Abstract:In order to explore the structure-activity correlation of benzothiadiazine series as inhibitors of genotype 1a HCV polymerase, a set of ligand- and receptor-based 3D-QSAR models were, for the first time, developed in the present work employing Comparative Molecular Field Analysis (CoMFA) and Comparative Molecular Similarity Index Analysis (CoMSIA) for 239 promising molecules. In addition, homology modeling, docking analysis, and molecular dynamics simulation (MD) were also applied to elucidate the probable binding modes of these inhibitors at the allosteric site of the enzyme. The statistical model validations assure the reliability of the obtained QSAR models. Changes in the binding affinity of the inhibitors attributing to modifications in the aromatic rings could be rationalized by the steric, electrostatic, hydrophobic, and hydrogen bond acceptor properties. (i) Hydrophobic substituents with similar size of benzo group like isosteres are preferential at positions 1 and 2 (ring B of benzothiadiazines). (ii) Substituents at position-3 containing a linear alkyl chain (four or five carbon atoms) or a branched alkyl chain (five-eight carbons) can increase the inhibitory activity by one to two orders of magnitude. (iii) A polar substituent like methanesulfonamide group at position-14 can enhance the activity of the drug by providing a hydrogen bonding interaction with the protein target. The results obtained from this work provide important guidelines in design of novel benzothiadiazine analogs as inhibitors of HCV genotype 1a NS5B. Keywords: HCV NS5B, benzothiadiazine analogs, allosteric site, 3D-QSAR, CoMFA, CoMSIA, molecular docking, molecular dynamics

Quinoxalin-2(1H)-One Derivatives As Inhibitors Against Hepatitis C Virus

Structure–activity relationship studies on quinoxalin-2(1 H )-one derivatives containing thiazol-2-amine against hepatitis C virus leading to the discovery of BH6870

Discovery of 5-Alkyl-2-pyrazol-oxazolidin-4-one Derivatives As Novel Hepatitis B Virus Capsid Assembly Modulators

Discovery of Novel 3-Hydroxyquinazoline-2,4(1h,3h)-dione Derivatives: A Series of Metal Ion Chelators with Potent Anti-HCV Activities.

2-((4-Arylpiperazin-1-yl)methyl)benzonitrile Derivatives as Orally Available Inhibitors of Hepatitis C Virus with a Novel Mechanism of Action

Discovering novel anti-HCV compounds with inhibitory activities toward HCV NS3/4A protease

Discovery Of Metal Ions Chelator Quercetin Derivatives With Potent Anti-Hcv Activities

Design, Synthesis, Molecular Modeling Studies and Biological Evaluation of N'-Arylidene-6-(benzyloxy)-4-oxo-1,4-dihydroquinoline-3-carbohydrazide Derivatives as Novel Anti-HCV Agents

Synthesis, Characterization, and Biological Evaluation of Some Novel Quinoxaline Derivatives as Antiviral Agents

Discovery of Quinoxaline-Based P1–P3 Macrocyclic NS3/4A Protease Inhibitors with Potent Activity against Drug-Resistant Hepatitis C Virus Variants

The discovery of indole derivatives as novel hepatitis C virus inhibitors

A novel class of meso-tetrakis-porphyrin derivatives exhibits potent activities against hepatitis C virus genotype 1b replicons in vitro

Flavonoid-triazolyl hybrids as potential anti-hepatitis C virus agents: Synthesis and biological evaluation

Studies of Benzothiadiazine Derivatives As Hepatitis C Virus NS5B Polymerase Inhibitors Using 3D-QSAR, Molecular Docking and Molecular Dynamics.

Structure-activity Relationships of Cryptopleurine Analogs with E-ring Modifications As Anti-Hepatitis C Virus Agents.

Insight into the structural requirements of benzothiadiazine scaffold-based derivatives as hepatitis C virus NS5B polymerase inhibitors using 3D-QSAR, molecular docking and molecular dynamics

Tetrazole and Triazole As Bioisosteres of Carboxylic Acid: Discovery of Diketo Tetrazoles and Diketo Triazoles As Anti-Hcv Agents.

QSAR of 1-cyclopropyl-6-fluoro-7-substituted-1,4-dihydro-4-oxoquinoline-3-carboxylic acids for anti-HTV activity

Discovery of functionalized bisimidazoles bearing cyclic aliphatic-phenyl motifs as HCV NS5A inhibitors.

2,4-Diaryl-4,6,7,8-tetrahydroquinazolin-5(1h)-one Derivatives As Anti-Hbv Agents Targeting at Capsid Assembly

Synthesis and Anti‐HBV Activities Evaluation of New Ethyl 8‐imidazolylmethyl‐7‐hydroxyquinoline‐3‐carboxylate Derivatives in Vitro